Eli Lilly (LLY) posted a second-quarter outcome robust sufficient to shift the controversy round its inventory.
For months, the controversy centered on one fear: a gradual begin for its new weight problems capsule. That fear didn’t disappear within the second quarter, however it stopped driving the dialog.
Financial institution of America got here out of the earnings name pointing to a distinct quantity.
The financial institution thinks the weight problems market exterior the US might finally surpass U.S. gross sales of the identical medication.
For anybody holding LLY or contemplating it, that worldwide name is price a better look.
Why Financial institution of America raised its Eli Lilly worth goal after the quarter
Financial institution of America lifted its worth goal on Eli Lilly (LLY) to $1,344 from $1,334, in line with a BofA World Analysis report shared with me.
The financial institution stored its math easy, making use of an unchanged 28.5 occasions a number of to its up to date 2027 underlying earnings estimate, which removes one-time analysis expenses.
Extra Well being Care Shares:
That a number of sits above what BofA makes use of for different massive drugmakers. Lilly is increasing quicker than its friends, so the financial institution pays extra for every greenback of future revenue.
The increase adopted a second quarter that beat expectations.
Lilly reported income of $23.0 billion, up 48% from a yr earlier, and adjusted earnings of $8.38 a share in opposition to a $6.01 consensus, CNBC reported.
Lilly additionally raised its full-year income forecast to $85 billion to $87 billion, up from $82 billion to $85 billion, in line with a press launch.
The worldwide weight problems market that might outgrow the U.S.
For years, the U.S. drove virtually all of Lilly’s weight problems gross sales. That’s altering rapidly, and it’s the shift BofA flagged for traders.
The financial institution famous that GLP-1 gross sales in worldwide weight problems markets at the moment are approaching parity with the U.S.
GLP-1 medication are a category of medicines, bought as injections and now tablets, that deal with diabetes and weight problems by curbing urge for food, BioPharma Dive reported.
Mounjaro, Lilly’s diabetes injection, grew 55% in Europe, 30percentin Japan, and 93% in China final quarter.
That progress is why BofA believes the non-U.S. alternative might finally surpass the house market, since most massive international locations have much more untreated sufferers than the U.S. does.
Financial institution of America sees Eli Lilly’s weight problems franchise increasing quicker abroad than at dwelling.JHVEPhoto / Getty Photos
What the Foundayo launch overseas means for Lilly’s subsequent leg
The clearest catalyst BofA cited is Foundayo, Lilly’s oral GLP-1 capsule.
Foundayo issues as a result of it is a capsule, not a shot. That opens the drug to sufferers who will not take a weekly injection, a bunch Lilly’s different therapies have by no means reached.
Its U.S. debut was modest. Foundayo introduced in $98 million, barely beneath the roughly $103 million analysts anticipated, CNBC reported.
BofA is wanting previous that quantity and expects the worldwide launch to matter extra, estimating roughly 60% of Foundayo’s peak gross sales to come back from exterior the U.S.
That launch is shut. Lilly has filed for approval in additional than 40 international locations and plans an abroad rollout in early 2027, BioPharma Dive reported.
Each Lilly and rival Novo Nordisk (NVO) described robust pent-up demand for an oral possibility overseas, the place injectables have confronted provide limits, Fierce Pharma reported.
On July 1, Medicare’s GLP-1 Bridge program went stay, opening obesity-drug protection to about 20 million eligible beneficiaries.
BofA stated early suggestions from Lilly and Novo factors to clean entry, with most early adoption coming from sufferers new to GLP-1 remedy.
Tens of millions of older Individuals who couldn’t beforehand get these medication now can, widening the paying buyer base.
Lilly advised analysts that Bridge sufferers can get each oral and injectable GLP-1s, although injectables stay the early desire.
The pricing trade-off traders preserve watching
U.S. GLP-1 costs preserve falling as extra sufferers are available by cash-pay channels and packages like Bridge.
BofA pegged second-quarter U.S. internet gross sales at about $580 per prescription, down 15% from a yr earlier however flat from the prior quarter.
That drop was milder than the financial institution had modeled. Nonetheless, BofA expects the blended U.S. worth to maintain falling by the second half of 2026 as cheaper channels develop.
Lilly’s administration calls the trade-off price it, as a result of quantity is rising quicker than worth is falling. That very same sample carried the inventory by the primary quarter.
Buyers ought to watch this intently, as a result of the decision is dependent upon demand outrunning costs. If quantity ever stalls whereas costs fall, the case turns rapidly.
The place Lilly’s pipeline retains it forward of rivals
The financial institution stated Lilly stays a step forward of opponents, pointing to late-stage belongings that might prolong its lead previous right this moment’s medication.
Two names anchor that view:
Retatrutide, a next-generation triple-hormone shot that posted weight reduction approaching bariatric-surgery ranges in Section 3 trials, in line with a press launch. Its U.S. submitting is deliberate for the primary quarter of 2027.
Eloralintide, an amylin-based drug BofA simply added to its Lilly mannequin, reflecting how a lot depth the pipeline now carries.
The takeaway for traders is that Lilly doesn’t depend on only one product. Even when Foundayo’s U.S. gross sales stay gradual, the corporate has a number of methods to increase its franchise.
What LLY traders ought to do with this
Lilly closed at $1,192.52 on Aug. 6, up 1.94% on the day and up 3.83% over the prior 5 periods. That is additionally close to its 52-week excessive of $1,249.45.
At that stage, BofA’s $1,344 goal implies a few 13% improve over the following yr.
Just a few issues to bear in mind earlier than performing:
The inventory trades at a price-to-earnings ratioaround 40, so lots of future progress is already priced in.
One weak quarter on quantity or pricing might hit the shares laborious at this valuation.
The worldwide launch is the true swing issue, and it doesn’t start in earnest till early 2027.
The case for proudly owning Lilly rests on demand rising quicker than costs fall, at dwelling and overseas. The second quarter confirmed that sample nonetheless holds, which is why BofA raised its goal.
Anybody contemplating LLY ought to dimension a place to their very own threat tolerance, and keep in mind that even a dominant firm can see a pointy pullback when expectations run this excessive.
